Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis
- 1 October 2016
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 171, 18-24
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patientsNeurology, 2016
- Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathyAnnals of Neurology, 2014
- Fingolimod after natalizumab and the risk of short-term relapseNeurology, 2014
- l -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNeurology, 2013
- Severe relapses under fingolimod treatment prescribed after natalizumabNeurology, 2012
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2012
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology, 2011
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyNeurology, 2009
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrinNature, 1992